A Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ABT-126 in Stable Subjects With Schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2010
At a glance
- Drugs Nelonicline (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- 18 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2010 New trial record